• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine

tetano

Editor, Senior Moderator
Vaccine. 2017 Oct 31. pii: S0264-410X(17)31358-0. doi: 10.1016/j.vaccine.2017.09.086. [Epub ahead of print]
[h=1]Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine.[/h] Yan J[SUP]1[/SUP], Morrow MP[SUP]1[/SUP], Chu JS[SUP]2[/SUP], Racine T[SUP]3[/SUP], Reed CC[SUP]1[/SUP], Khan AS[SUP]1[/SUP], Broderick KE[SUP]1[/SUP], Kim JJ[SUP]1[/SUP], Kobinger GP[SUP]3[/SUP], Sardesai NY[SUP]1[/SUP], Weiner DB[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Despite the routine development and distribution of seasonal influenza vaccines, influenza remains an important pathogen contributing to significant human morbidity as well as mortality each year. The seasonal variability of influenza creates a significant issue for vaccine development of seasonal strains that can afford protection from infection or disease based on serotype matching. It is appreciated that the globular head of the HA antigen contained in the vaccines generates antibodies that result in HAI activity that are a major correlates of the protection against a particular strain. Due to seasonal genetic changes in the HA protein, however, new vaccine strains are needed to be developed continually to match the new HA antigen of that seasons virus. A distinct advantage in seasonal vaccine development would be if a small group of antigens could be developed that could span many seasons without needed to be replaced due to this genetic drift. Here we report on a synthetic microconsensus approach that relies on a small collection of 4 synthetic H1HA DNA antigens which together induce broad protective HAI immunity spanning decades of H1 influenza viruses in mice, guinea pigs and non-human primates. The protective HAI titers induced by microconsensus immunogens are fully functional in vivo as immunized ferrets were completely protected from A/Mexico/InDRE4487/2009 virus infection and morbidity associated with lethal challenge. These results are encouraging that a limited easy-to-formulate collection of invariant antigens can be developed which can span seasonal vaccine changes allowing for continued immune protection.
Copyright ? 2017. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] DNA vaccine; Electroporation; HIHA antigens; Influenza; Microconsensus

PMID: 29100705 DOI: 10.1016/j.vaccine.2017.09.086
 
Back
Top Bottom